Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
yep indeed, what a strange thing to say. That very question was asked at the investormeet pres, and we were informed that they are not looking for that, and yes i know placings can be made as and when and a company are not going to advertise the fact they are looking at that.
Steve: This is the news that we know is in the works:
New COO will come in anytime, timelines are down to various factors.
DoseMe update should be made, timeline unknown.
VAL201 update, timeline unknown ( Ask the VAL shareholders!)
Any other deal(s) that are in the pipeline could come to fruition.
I still think that the dosing tool is awaiting news to, ie more updates, patents? collabs etc?
by over 3% yesterday on minimal volume. Apparently NT most of the time.
https://www.physiomics.co.uk/wp-content/uploads/2023/04/AACR2023_Abstract-Number-5699.pdf
A B&I ( bed & isa ) went thru earlier.
The PI had 250k, and ended after the switch with 248k+
We may never know how many people are in the room to listen to the presentation. However, it has to be a lot better presenting to a live audience than just presenting a poster at a specific time. The huge question is, how many deal(s) let alone interest will come from this presentation?
Indeed, good to see the volume of buys. Last week, many of the buys were dressed in red.
For those that want to see the "link" its here: https://www.abstractsonline.com/pp8/#!/10828/presentation/8054 This came from the RNS on london stock exchange, which is not being highlighted by this website??
Well my prediction of a RNS on 18th, was 4 days early.
https://www.bbc.co.uk/news/uk-wales-65180208
This its another way to aid early detection and therefore treatment of Prostate Cancer.
To me, the presentation seemed a lot more "personal" this time, by that JM seemed more human, and not like a talking robot like the last few times. He seemed very contrite and was very apologetic, especially over the update on the partner study. I feel a tad vindicated when some were saying the Beyond Blood RNS was the update, it clearly was not.
I am sure others both pro/negative here may well say the their pieces on it, but the explanation of the Merck £ drop was fair, and it seems they were stuck between a rock and hard place whether to release the update before the Merck news, so decided to update on both at same time?
He answered a lot of Questions, some which he has not answered before, however he failed to answer a question about the BOD buying shares, yes, hes answered this in the past, but was hoping that the answer may have changed?
Others will quite rightly concentrate on the financial side of the presentation, however, 2 things that stick out for me is their aim to get the board re-jigged and in line with other companies structures board wise (Maybe these new appointments whenever they happen will buy stock!) We knew they are going to AACR in mid April, we thought they would be doing a "abstract" poster session, turns out they have been "upgraded"
Session MS.BCS02.01 - Clinical Applications of Artificial Intelligence and Mathematical Oncology
5699 - Development and validation of a quantitative systems pharmacology model for prediction of preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined with the ATR inhibitor gartisertib (M4344)
April 18, 2023, 4:07 PM - 4:22 PM Valencia BC - Convention Center
Looking at the photos, its Hayley, Nathalie and Christophe presenting in front of a audience, something which i have not seen them do at AACR conference level (ever)??
Looking at the "disclosures" of the authors/attendees is interesting, and in some way clarifies what JM said in a question of staff and their rolls within the company.
So its back to the long game here, next we should get a RNS on April 18th confirming AACR presentation slides etc. New COO in the next few months? Any of the potential 25 in the "pipeline" may come to fruition. Doseme update? VAL201?
Error, states 0900 yesterday.
Looks like a error with Investormeet? You should be able to ask Q's up to 0900 this morning, but myself, and others appear not to be able to.
If you need to ask Q's pls email info@physiomics.co.uk and get them submitted.
The webinar is now on company website for those interested.
https://www.physiomics.co.uk/wp-content/uploads/2023/03/Mathematical-modelling-in-the-age-of-Project-Optimus-20230330_143359-Meeting-Recording.mp4
A few days ago Steve, you suggested i was doubting it, sounds like you are to?
Large trade of aprox £24k just popped up at 3p from yesterday At the time of the trade the SP was 2.50 - 2.70 so i am thinking its a buy? bwthdik.
Very very disappointing day. There is not much i can or want to say tbh. some good things in the RNS, some not so good. I mentioned in Dec / Jan about the Merck MSA not being renewed, and at last JM has come clean about that. For me, the new COO cant come soon enough imho.
We will get a RNS prob about 18th April stating about the AACR presentation. Pretty disillusioned here to be honest/
Interesting about new COO: -- The Company is actively recruiting for a COO role to optimally support its growth in current and potential new consulting areas. It is anticipated that this individual, should the Company be successful in its recruitment process, will take on significant responsibilities from the Executive Chairman / CEO
Will JM be taking a back seat once the new COO is in place?
Dr Millen will make a live presentation on this update via Investor Meet Company on 6 April 2023 at 3:00pm BST which will be open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation
Laura, the collab with Beyond Blood is nothing to do with the partner tool what so ever.
As stated earlier, BB are using PYC to validate their figures and that is it.
Yes, there are hopefully more deals to be signed.
Clarets....no, not sold any.
Steve, disappointment yes, hopeful that they will turn a profit, and what do you define as a decent level?
Having not watched it live, and i know that some people were not able to watch it, even thou they were registered ( that could be the fault of eventbrite )those that have watched it are underwhelmed to say the least. There was a Q&A session afterwards, but not much came from that as JM and HM chose what Q's to answer.
It appears that when they said on Jan 9th "Dr Jim Millen, CEO commented: "I believe that the PARTNER study, as the culmination of several years of grant funded work, offers a significant opportunity for Physiomics to engage in the emerging personalised dosing space, either alone or in partnership with other complementary technologies. We'll be actively following up the areas noted above and will provide an update to shareholders before the end of Q1 2023." JM was obviously hinting at the Beyond Blood RNS. However, my anger towards this is this: The PARTNER study is not involved in anyway with BB. All BB are doing is using PYC tech to validate their figures. So when he says PARTNER study either alone or complimentary, i believe that is totally wrong.
The BB collab to me was indicated on this line in the Jan 9th RNS " The tool would be highly synergistic with a device that can measure blood cells counts in community or out-patient settings and this will be further explored by Physiomics during the current quarter" Again, nothing along the lines of the PARTNER study, or the dosing tool etc, unless this "update" happens today, JM has not delivered on the above statement about a end of Q1 update.